KRAS and lung adenocarcinoma: However, for the 12 trials enrolling patients with non-specified NSCLC histology but with mandatory presence of EGFR mutations (n = 6), ALK rearrangements (n = 5), or KRAS mutations (n = 1), the vast majority of enrolled patients (> 90% for each study) had a diagnosis of lung adenocarcinoma.